Mucinous breast carcinoma: A single-center experience
Özet
OBJECTIVE To analyze the clinical and histopathological characteristics and treatment outcomes of patients treated and followed up for mucinous breast cancer (MBC). METHODS We retrospectively analyzed the clinical and histopathological characteristics and treatment outcomes of 22 patients who were diagnosed with and treated for MBC at our center between 2004 and 2016. RESULTS The mean age was 50 (range: 26–68) years. Ten (47.6%) patients were premenopausal. The tumor was in the right side in 11 patients (50%), and 64% of the patients had early-stage disease. There were six patients with the mixed subtype and 16 with the pure subtype. Except for the two patients with metastatic disease, all patients underwent surgery. Axillary lymph node involvement was detected in seven (36%) patients, and the proportion of patients with the pure subtype was 18%. The average duration of follow-up was 59 months, during which, four patients had recurrent disease. At 5 years, 81% of the patients were alive. The 5-year overall survival rate with pure MBC was 93%. CONCLUSION MBC is a rare condition and carries a good prognosis. Pure MBC has low axillary lymph node metastasis and a higher survival rate. © 2018, Turkish Society for Radiation Oncology.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Yildirim, Nilgün | |
| dc.contributor.author | Aldemir, Mehmet Naci | |
| dc.date.accessioned | 2026-10-18T20:29:03.441386392Z | |
| dc.date.available | 2026-10-18T20:29:03.441386392Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | OBJECTIVE To analyze the clinical and histopathological characteristics and treatment outcomes of patients treated and followed up for mucinous breast cancer (MBC). METHODS We retrospectively analyzed the clinical and histopathological characteristics and treatment outcomes of 22 patients who were diagnosed with and treated for MBC at our center between 2004 and 2016. RESULTS The mean age was 50 (range: 26–68) years. Ten (47.6%) patients were premenopausal. The tumor was in the right side in 11 patients (50%), and 64% of the patients had early-stage disease. There were six patients with the mixed subtype and 16 with the pure subtype. Except for the two patients with metastatic disease, all patients underwent surgery. Axillary lymph node involvement was detected in seven (36%) patients, and the proportion of patients with the pure subtype was 18%. The average duration of follow-up was 59 months, during which, four patients had recurrent disease. At 5 years, 81% of the patients were alive. The 5-year overall survival rate with pure MBC was 93%. CONCLUSION MBC is a rare condition and carries a good prognosis. Pure MBC has low axillary lymph node metastasis and a higher survival rate. © 2018, Turkish Society for Radiation Oncology. | |
| dc.identifier.doi | 10.5505/tjo.2018.1727 | |
| dc.identifier.endpage | 47 | |
| dc.identifier.issn | 1300-7467 | |
| dc.identifier.issue | 2 | |
| dc.identifier.scopus | 2-s2.0-85048298425 | |
| dc.identifier.startpage | 43 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/14265 | |
| dc.identifier.volume | 33 | |
| dc.identifier.wos | WOS:000436167800001 | |
| dc.language.iso | en | |
| dc.publisher | Istanbul Tip Fakultesi | |
| dc.relation.ispartof | Turk Onkoloji Dergisi | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Mucinous breast cancer | |
| dc.subject | Prognosis | |
| dc.subject | Treatment | |
| dc.subject | epidermal growth factor receptor 2 | |
| dc.subject | estrogen receptor | |
| dc.subject | progesterone receptor | |
| dc.subject | adult | |
| dc.subject | aged | |
| dc.subject | Article | |
| dc.subject | breast carcinoma | |
| dc.subject | cancer chemotherapy | |
| dc.subject | cancer prognosis | |
| dc.subject | cancer staging | |
| dc.subject | clinical article | |
| dc.subject | female | |
| dc.subject | histopathology | |
| dc.subject | human | |
| dc.subject | human tissue | |
| dc.subject | lymph node metastasis | |
| dc.subject | male | |
| dc.subject | mastectomy | |
| dc.subject | metastasis | |
| dc.subject | mucinous breast carcinoma | |
| dc.subject | outcome assessment | |
| dc.subject | overall survival | |
| dc.subject | premenopause | |
| dc.subject | protein expression | |
| dc.subject | retrospective study | |
| dc.subject | tumor localization | |
| dc.subject | tumor volume | |
| dc.title | Mucinous breast carcinoma: A single-center experience | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 2 | |
| rdl.citation.trdizin | 0 | |
| rdl.citation.wos | 1 | |
| rdl.department | ERZİNCAN BİNALİ YILDIRIM ÜNİVERSİTESİ | |
| rdl.department | T.C. SAĞLIK BAKANLIĞI | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | TRDIZIN | |
| rdl.wos.index | Emerging Sources Citation Index (ESCI) |
